1. Home
  2. SF vs BBIO Comparison

SF vs BBIO Comparison

Compare SF & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SF
  • BBIO
  • Stock Information
  • Founded
  • SF 1890
  • BBIO 2015
  • Country
  • SF United States
  • BBIO United States
  • Employees
  • SF N/A
  • BBIO N/A
  • Industry
  • SF Investment Bankers/Brokers/Service
  • BBIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • SF Finance
  • BBIO Health Care
  • Exchange
  • SF Nasdaq
  • BBIO Nasdaq
  • Market Cap
  • SF 9.8B
  • BBIO 8.0B
  • IPO Year
  • SF N/A
  • BBIO 2019
  • Fundamental
  • Price
  • SF $109.20
  • BBIO $45.60
  • Analyst Decision
  • SF Hold
  • BBIO Strong Buy
  • Analyst Count
  • SF 8
  • BBIO 14
  • Target Price
  • SF $105.14
  • BBIO $58.85
  • AVG Volume (30 Days)
  • SF 673.5K
  • BBIO 3.3M
  • Earning Date
  • SF 07-23-2025
  • BBIO 07-31-2025
  • Dividend Yield
  • SF 1.68%
  • BBIO N/A
  • EPS Growth
  • SF 19.51
  • BBIO N/A
  • EPS
  • SF 5.24
  • BBIO N/A
  • Revenue
  • SF $5,030,597,000.00
  • BBIO $127,415,000.00
  • Revenue This Year
  • SF $7.38
  • BBIO $102.05
  • Revenue Next Year
  • SF $9.94
  • BBIO $54.69
  • P/E Ratio
  • SF $20.83
  • BBIO N/A
  • Revenue Growth
  • SF 14.86
  • BBIO N/A
  • 52 Week Low
  • SF $73.27
  • BBIO $21.72
  • 52 Week High
  • SF $120.64
  • BBIO $45.48
  • Technical
  • Relative Strength Index (RSI)
  • SF 79.87
  • BBIO 66.67
  • Support Level
  • SF $96.54
  • BBIO $41.80
  • Resistance Level
  • SF $98.33
  • BBIO $45.48
  • Average True Range (ATR)
  • SF 2.18
  • BBIO 1.57
  • MACD
  • SF 0.93
  • BBIO -0.01
  • Stochastic Oscillator
  • SF 99.26
  • BBIO 78.42

About SF Stifel Financial Corporation

Stifel Financial is a middle-market-focused investment bank that produces more than 90% of its revenue in the United States. Approximately 67% of the company's net revenue is derived from its global wealth management division, which supports over 2,000 financial advisors, with the remainder coming from its institutional securities business. Stifel has a history of being an active acquirer of other financial-services firms.

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Share on Social Networks: